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T Cell Expansion: The Survivin
Interface between Cell
Proliferation and Cell Death
i
T cell proliferation is tightly controlled by intersecting c
signaling networks. In this issue of Immunity, Song et A
al. (2005) uncover Survivin as a new mediator of this p
process. Abundantly studied as a cancer gene, Sur- w
vivin now emerges as an essential arbiter of T cell o
expansion, coupling cell cycle progression to apopto- (
sis resistance. m
t
Only a few genes have been more often designated as m
“controversial” than Survivin. A member of the inhibitor o
of apoptosis (IAP) gene family (Salvesen and Duckett, b
2002), Survivin has engendered deep passions and f
given researchers from various disciplines nearly end- c
Sless opportunities to disagree. Despite this, or precisely
because of this, Survivin is very popular in research t
nlabs, generating more citations in Medline than all other
IAP proteins combined. So, what is so special or con- a
troversial about Survivin? To appreciate the new find-ngs published by Song et al. (2005), it may be helpful
o quickly review the issues at hand. (1) Survivin is in-
ispensable. Knockout studies show a very early em-
ryonic phenotype, and every possible Survivin knock-
own approach, conditional deletion, or molecular
nterference invariably shuts down cell proliferation and
auses cell death. (2) Survivin is essential for mitosis.
mitotic gene tightly controlled by transcriptional and
osttranscriptional mechanisms, Survivin associates
ith the mitotic apparatus and allows safe completion
f mitosis, possibly by regulating microtubule stability.
3) Survivin is a cancer gene. Virtually every human tu-
or overexpresses Survivin, and by molecular profiling,
his means poor outcome. (4) In addition to controlling
itosis, Survivin also inhibits apoptosis. The literature
verwhelmingly shows that Survivin blocks apoptosis,
ut does this imply that Survivin can really be a two-
aced Janus, controlling cell division while inhibiting
ell death? (5) And what about normal cells? Typically,
urvivin expression is low to undetectable in normal
issues, but is there nevertheless a role for Survivin in
ormal cells? And if there is, what is it? Inhibition of
poptosis? Control of mitosis? Both? Neither?
Now, Song et al. (2005) provide some key answers
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535and move some “controversies” to the “facts” column.
In continuing their studies on T cell activation, Song et
al. (2005) now show that Survivin becomes prominently
induced in T cells costimulated by OX40 ligation. This
pathway obligatorily requires Akt and is fully recapitu-
lated by Akt signaling. Growth factor signals have been
shown before to trigger Survivin expression in normal
cells (endothelium or smooth muscle cells), and Akt has
been known to mediate these responses (Altieri, 2003).
But here is the first surprise. Costimulated T cells do
not express Survivin at mitosis but rather at the G1/S
transition of the cell cycle, and even when cell cycle
progression is impaired, costimulated T cells still over-
express Survivin at G1/S. Then, a second surprise fol-
lows. Not only is Survivin expressed in OX40-stimulated
T cells, but also its retroviral introduction in OX40-defi-
cient cells is sufficient, as a single gene, to restore their
proliferative defect in both culture assays and in vivo.
There is little room to argue with the data presented
by Song et al. (2005), as this response unambiguously
involves a dual effect of Survivin in pushing T cells past
the G1/S transition with dramatic expansion of the S
phase fraction and in nearly ablating apoptosis, as
measured by Annexin V labeling. The reverse is also
true, and blocking Survivin in costimulated T cells with
a well-characterized dominant-negative mutant pre-
vents cell cycle progression and induces T cell apopto-
sis. There is also a third surprise. Survivin is not just a
broad antiapoptotic stimulus keeping T cells alive any-
time, anywhere. In fact, this pathway works only during
the rather narrow temporal window of T cell expansion.
Differently from other cytoprotective factors, like Bcl-2,
Song et al. (2005) find that Survivin cannot rescue T
cells after clonal contraction has occurred, some 14
days after immunization, in vivo.
The innovative findings by Song et al. (2005) open
tantalizing new prospects on several grounds. First,
Survivin enters cellular immunology as a new and
essential regulator of T cell clonal expansion. Because
CD28 ligation also reproduces the effect of OX40 in in-
ducing Survivin expression, this is likely to be a general
requirement of T cell activation. So, there is clearly a
role of Survivin in normal cells, and it is an essential
one. Second, Survivin is required for both proliferation
and inhibition of apoptosis of expanding T cells, and
the data by Song et al. (2005) clearly show that these
two processes are so interdependent that they cannot
be functionally or temporally dissociated. It is hard to
say which comes first, whether T cells expressing Sur-
vivin can proliferate and therefore do not die or whether
Survivin keeps them healthy so that they can expand.
Regardless, the data by Song et al. (2005) make it clear
that not all survival proteins are created equal, and Sur-
vivin serves a unique function by coupling both cyto
protection and cell proliferation during the critical time
frame of the initial clonal expansion of T cells. In addi-
tion, the new data by Song et al. (2005) demonstrate
that in T cells, Survivin is actually not a mitotic genebut rather a regulator of the G1/S transition. This finding
is reminiscent of similar data obtained with Survivin
conditional knockout thymocytes (Okada and Mak,
2004) but is at odds with the results of several Survivin
knockdown studies in epithelial cells, showing a phe-
notype of prometaphase arrest, suggesting that S
phase transition had occurred normally (Lens et al.,
2003). Regardless, a simplistic model that Survivin’s
role in the cell cycle obligatorily depends on mitotic
proteins, like Aurora B (Adams et al., 2001), is no longer
plausible. It is now clear that Survivin can operate at
much earlier phases of the cell cycle, i.e., at the G1/S
transition when Aurora B is not even expressed, sug-
gesting a continuum of functions throughout various
transitions and checkpoints of the cell cycle. But what
drives Survivin expression at G1/S? And how does Sur-
vivin so dramatically promote S phase progression?
These are clearly questions for follow-up studies, but
an attractive candidate for the first point is E2F, a pleio-
tropic transcriptional regulator of the G1/S transition
that has been shown to induce Survivin expression
(Jiang et al., 2004).
Lastly, is there a “translational,” disease-relevant
message in the findings by Song et al. (2005)? One cer-
tainly comes to mind. Several ongoing cancer trials are
using molecular antagonists of Survivin (Altieri, 2003).
So, extrapolating from the results of Song et al. (2005),
does it mean that Survivin antagonists may also pro-
vide attractive immunosuppressive agents, shutting off
T cell expansion without affecting long-term memory T
cells? Time will tell. For now, returning to the question
of what is so special about Survivin, one answer may
be its fascinating complexity, with many independent
functions in multiple cellular contexts integrated into a
single 142 amino acid protein.
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